Actavis, the international generic pharmaceutical company, has entered into an exclusive distribution agreement, for a number of generic products, with J&M Pharma, Co Ltd, a Korean owned and operated pharmaceutical company, headquartered in Seoul, Korea. The agreement is an important step in building Actavis’ presence in the Korean generics market.
Actavis has operations in 40 countries, with 11,000 employees and is one of the world’s leading generic pharmaceutical companies specialising in the development, manufacture and sale of generic pharmaceuticals. Actavis’ products are already marketed in the Asia Pacific region, in markets including Singapore, Hong Kong, China, Australia, Indonesia, Taiwan, Malaysia and Vietnam.
Commenting on this partnership Thomas Runkel, Vice President of Actavis in the Asia Pacific region said: “The partnership with J&M is an important milestone for our entrance into the fast growing Korean market. We look forward to working with J&M to bring our extensive generic product portfolio of first class generics onto the Korean market fast.”
Tae-Hwan Kim, President of J&M, said: “We are excited to enter into an exclusive distribution agreement with Actavis for selected generic products. We will strive to position Actavis as a trusted generic brand in the Korean market and make a success story with its esteemed products.”
Andrew Suh, CEO of Cosmo USA IBRC, Inc. (www.cosmo-usa.com), a life science industry consulting company, served an integral role in bringing Actavis and J&M together for this opportunity.
More information about Actavis Group can be found at www.actavis.com
Enquiries:
Actavis Asia/Pacific
Thomas Runkel
Vice President
Tel: (+62) 218 710311 ext 222
E-mail: trunkel@actavis.com
Actavis Group
Hjordis Arnadottir
Director, External Communications
Tel: (+354) 535 2300 / 840 7476
E-mail: harnadottir@actavis.com
